BOSTON--(BW HealthWire)--Nov. 5, 1999--
Evidence of a Universal Immune Response by the Body to Cancer,
Patent Granted, and First Synthetic General
Cancer Vaccine Developed
See www.cancerimmune.com, www.antimaligninantibody.com &
www.amascancertest.com.
The first direct evidence in substantial human populations of a universal immune defense against human cancer was just presented to the American Association for Cancer Research. 3 laboratories studied 8,090 people. Antimalignin antibody in serum (AMAS) was shown to be a specific Immunosurveillant(TM) which is cytotoxic to cancer cells, regardless of cell type. Previously, indirect evidence only, such as the higher frequency of certain cancers in immunosuppressed individuals (as in AIDS) suggested that immune system defenses against cancer may exist, but there has been no direct evidence of cancer immune(TM) processes in substantial human populations. Now direct immunochemical evidence from the AMAS(R)Test shows we are all at first cancer immune and quantitates the challenges to that immune status. The US Patent Office has granted Samuel Bogoch,M.D.,Ph.D. a Patent (No.5,866,690) for this unique immunological approach and new products for the early detection and treatment of cancer.
Human antimalignin antibody is perhaps the most potent specifically anticancer substance known. Isolated in vivo or produced in vitro, it is cytotoxic/cytostatic to malignant cells in vitro at picograms (femtomoles) per cancer cell. Antimalignin antibody, universally present in human serum, increases in concentration with age as the risk of cancer increases. Unaffected individuals from high-risk families in their 20's are already producing as much antimalignin antibody as individuals in their 60's from low-risk families. The antibody increases even more markedly with clinical cancer regardless of cell type.
Millennium Change to a New Era of Cancer Diagnosis and Prevention
The old practice of waiting for a mass to appear before clinical cancer can be diagnosed and treated is already being superseded by the use of the AMAS(R)Test in practice for earlier diagnosis and treatment, especially in high risk individuals.
Further, antimalignin antibody was found by actuarial survival studies to be quantitatively directly related to survival of cancer patients; that is, the greater the antimalignin antibody concentration the longer the survival of cancer patients. Antimalignin antibody's concentration can now be increased either by injection of extra antibody produced in the laboratory, or by injection of synthetic vaccine to increase the antibody concentration. Oncolab has recently determined the structure of two stretches of the cancer cell antigen malignin by hydrolysis and mass spectrometry, then synthesized small peptides of identical sequence. When injected into animals these synthetic peptides produce specific antimalignin antibody in abundance. Thus, in addition to these synthetic peptides establishing rigorously the immunochemical basis of the production of antimalignin antibody, of the immunosurveillance process, and of the Test, they are the first general synthetic cancer vaccines. These synthetic general cancer vaccines may soon be used to increase the concentration of the antibody in human cancer prevention and treatment.
With the proven early pre-symptomatic detection of transformed cells rather than awaiting clinical cancer, and the production of the first synthetic general cancer vaccines for their destruction, we have entered the era of prevention of clinical cancer.
For references to publications in peer-reviewed journals from 1957 to the present from Drs. Samuel and Elenore Bogoch's laboratory, first at Harvard Medical School, then with Boston University School of Medicine, Foundation for Research on the Nervous System and Oncolab,Inc., see www.cancerimmune.com, www.antimaligninantibody.com and www.amascancertest.com. Cancer Immune and Immunosurveillant are trademarks of Brain Research, Inc. and Cancer Immune, Inc.
